|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of PLA2R-AB in longitudinal serum samples revealed seropositivity in 44% (59 out of 134) of primary MN cases, 3% (one out of 35) of secondary MN cases, and in 0% of healthy controls.
|
31843984 |
2020 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We describe a patient diagnosed with anti-phospholipase A2 receptor antibody positive membranous nephropathy and recurrent VTE while on therapeutic dosing of apixaban.
|
30421320 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In membranous nephropathy (MN), which is characterized by deposition of immune complexes along the glomerular basement membrane (GBM), phospholipase A2 receptor (PLA2R) and thrombospondin type 1 domain-containing 7A are target antigens in approximately 70% and 1%-5% of cases of primary MN, respectively.
|
31061139 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A (THSD7A) were identified as pathogenic antigens in patients with membranous nephropathy (MN).
|
31243053 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, these findings point out the important role of APLA2R as a tool to predict the disease course and establish personalized therapeutic options at the moment of diagnosis of primary MN.
|
30747150 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this editorial, we update the importance of anti-PLA2R levels as a prognostic marker in idiopathic MN at the diagnosis of the disease.
|
30747149 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
While the pathogenesis of MN is still controversial, the detection of autoantibodies against two specific glomerular antigens, phospholipase A2 receptor (PLA<sub>2</sub>R) and thrombospondin type 1 domain containing 7A (THSD7A), together with the beneficial effect of therapies targeting B cells, have highlighted the main role of autoreactive B cells driving this renal disease.
|
31788474 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic value of phospholipase A2 receptor in primary membranous nephropathy: a systematic review and meta-analysis.
|
31140029 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy.
|
31243451 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
It has been reported that phospholipase A2 receptor (PLA2R) is the first autoantigen involved in idiopathic membranous nephropathy and thrombospondin type-1 domain-containing 7A (THSD7A) may have a close relationship with malignancy-related membranous nephropathy.
|
31617780 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
While there is an increasing understanding of primary MN with the discovery of antibodies directed against phospholipase A2 receptor (PLA2R Ab) and thrombospondin type 1 domain-containing 7A, circulatory factors causative of inducing MCD and FSGS remain in part elusive.
|
31447217 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The discovery in 2009 of the M-type phospholipase A2 receptor (PLA2R) as the primary target in membranous nephropathy (MN) greatly advanced basic and clinical research.
|
31611068 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with IgG4-related MN have been characteristically negative for autoantibodies to the phospholipase A2 receptor (PLA2R).
|
31096469 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Autoantibodies both to the M-type phospholipase A2 receptor (PLA2R) and to thrombospondin type-1 domain-containing 7A (THSD7A), initially described in adult MN, have now been identified in children and adolescents with MN and serve as a useful diagnostic and monitoring tool in this younger population as well.
|
31811540 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The only exception is anti-phospholipase A2 receptor antibodies, which have been implemented successfully as a diagnostic and prognostic biomarker of membranous nephropathy.
|
30531471 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Circulating antibodies against M-type phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in Chinese patients with membranous nephropathy.
|
31227982 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies.
|
30665573 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presence of autoantibodies against podocyte antigens phospholipase A2 receptor (PLA2R) and thrombospondin type 1 domain containing 7A (THSD7A) in MN suggests an autoimmune mechanism.
|
30538665 |
2018 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The diagnostic performance of the phospholipase A2 receptor (PLA2R) and immunoglobulin G4 (IgG4) detection based on immunohistochemistry were evaluated using biopsy tissues of 59 primary and 56 secondary MGN cases for discrimination between primary MGN and secondary MGN.
|
28362702 |
2018 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy.
|
30541581 |
2018 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The phospholipase A2 receptor (PLA2R1) is the major autoantigen in primary membranous nephropathy.
|
29114041 |
2018 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A 45-year-old man with membranous nephropathy negative for serum anti-phospholipase-A2-receptor antibody, showed no response to corticosteroids and cyclophosphamide.
|
29924035 |
2018 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The utility of phospholipase A2 receptor autoantibody in membranous nephropathy after kidney transplantation.
|
29988247 |
2018 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antibodies against M-Type Phospholipase A2 Receptor May Predict Treatment Response and Outcome in Membranous Nephropathy.
|
30472708 |
2018 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our understanding of the pathogenesis of primary MN has advanced greatly with the identification of M-type phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A as target antigens whose antibodies serve as biomarkers of this disease.
|
29852477 |
2018 |